Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Jamie Cavenagh et al.|Blood|2024Cited by 78
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remissionJad Othman, Nigel H. Russell, Nicola Potter et al.|Blood|2024Cited by 75
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Ing Soo Tiong et al.|Blood|2023Cited by 65
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Nigel H. Russell, Charlotte S. Wilhelm-Benartzi et al.|Blood Advances|2023Cited by 53
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Leukemia|2023Cited by 48